Morton Goldberg is Director at EYEGATE PHARMACEUTICALS INC (EYEG). They have made 5 open-market trades across 1 company since 2016, most recently 2019-12-06.
CIK 0001372514
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EYEG | 1,961 | $68K |
Shares reported on the most recent Form 4, priced at the 2019-11-13 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EYEG | SELL | 2019-12-06 | 2019-12-06 | $6.93 | $14K | +7.0% | +34.1% | -19.3% |
| EYEG | SELL | 2019-11-12 | 2019-11-13 | $4.29 | $9K | +35.6% | +33.2% | +36.8% |
| EYEG | SELL | 2017-03-06 | 2017-03-06 | $3.00 | $27K | -15.3% | -17.8% | -31.7% |
| EYEG | SELL | 2016-06-15 | 2016-06-15 | $3.16 | $47K | -22.0% | -25.4% | -51.7% |
| EYEG | SELL | 2016-06-03 | 2016-06-07 | $3.31 | $72K | -0.6% | -23.4% | -44.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.